Bcl-2 Family Proteins in Human Health and Diseases
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: 15 September 2024 | Viewed by 65
Special Issue Editors
Interests: apoptosis/regulated cell death; death receptors; mitochondria; Bcl-2 family proteins; metabolism; respiration; cancer
2. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
Interests: regulation of cell death signaling in cancer cells; reactive oxygen species and cell fate; Bcl-2 family and mitochondrial metabolism; protein phosphatase PP2A and cancer; autophagy and cancer; experimental therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since the mid-1980s, when the founding member, the human Bcl-2, as a protein overexpressed in follicular B cell lymphoma was discovered, in the animal kingdom, the family of Bcl-2-related proteins has been recognized as major regulators and activators of (intrinsic) apoptotic signaling. In mammals, there are over 20 members of this remarkable family governing intrinsic/mitochondria-mediated apoptosis, as well as participating in other cell-death-unrelated signaling. Bcl-2 family proteins affect embryonic development and play important roles in human pathologies, mainly in cancer. Based on their structure and function in humans, Bcl-2 family proteins can be divided into three groups: a/anti-apoptotic proteins containing four Bcl-2 homology (BH) domains, such as Bcl-2 or Bcl-XL, b/multi-BH domain pro-apoptotic proteins such as Bax or Bak, and c/ single BH3-only domain containing sensitizing/activating members of this family, such as Bim, Bid, or Bad. Anti-apoptotic Bcl-2 family proteins are essential for the maintenance of the immune system, and their dysregulated/upregulated expression contributes to the initiation and progression of malignant diseases largely of hematopoietic origin. Structure–functional analyses of Bcl-2 family protein in the last 20 years have led to both fundamental discoveries in their apoptosis-related as well as -unrelated roles and to significant progress in the treatment of hematopoietic and likely other malignancies. Undoubtedly, proteins from the Bcl-2 family are having an impact on human health, are involved in human pathologies, and are exploited in the therapy of mainly cancer-linked pathologies.
Dr. Ladislav Anděra
Prof. Dr. Shazib Pervaiz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Bcl-2
- cancer
- signaling
- therapy
- apoptosis
- mitochondria
